Concepts in use of
(MTX) is used in the treatment of many malignancies, the benefit of using HDMTX
( 1 g/m2), as opposed to conventionally dosed MTX (<1 g/rn2), has been better appreciated in the treatment of childhood acute lymphocytic leukemia (ALL) and osteosarcoma [4] [5] [6] [7] [8] [9] [10] . Freeman et al. [5] reported that the systemic relapse rate was notably decreased in children with ALL treated with HDMTX compared with those receiving conventionally dosed MTX. Subsequently, Evans et al. [4] showed that a critical relationship existed between serum concentrations of MTX in children with ALL and the probability of remaining in remission. In the latter study, children with ALL who achieved a steady-state MTX concentration of 16 imoVL had a much better chance of remaining in remission vs those children with concentrations of 16 ,r.tmol/L. The optimal HDMTX dosing in childhood ALL, however, remains to be defined. In the studies by Evans et al. [4] , although all children received the same dose of HDMTX (1 g/m2), there was considerable variation in the steady-state serum concentrations of MTX attained (9.3-25.4 j.tmol/L). The authors concluded that variability in drug elimination between patients was responsible for the wide range in steady-state MTX concentrations and therefore in the patients' systemic exposure [4] . HDMTX also appears to be important in the treatment of central nervous system leukemia; although a head-to-head comparison of HDMTX with conventional-dose MTX in treating active CNS leukemia has not been performed, enough pilot studies experience exists to support a superior role for HDMTX in treating childhood CNS ALL [11] . MTX at conventional doses fails to adequately protect against CNS relapse [12] . This most likely reflects (as Shapiro et al. [13] have shown) the fact that barely cytotoxic concentrations of MTX (0.1 moVL) are achieved in the cerebrospinal fluid (GSF) when conventional doses of MTX (500 mg/rn2) are used. Conversely, HDMTX dosed at 33.6 g/rn2 was shown by Balis et al. [6] Reprinted by permission.
synthesis of these nucleotides (see Fig. 1 ). The concentration of MTX required to block cell growth has been studied by Chabner and Young [19] in healthy as well as in tumor-bearing mice by determining the in vivo incorporation of tritium-labeled deoxyuridine in bone marrow, intestinal mucosa, and ascitic L12 10 leukemic cells. Their studies showed that DNA synthesis returned to 50% of pretreatment rates at MTX plasma concentrations <10 nmol/L for bone marrow and ascitic leukemic cells and at <5 nmol/L for intestinal mucosal cells.
MTX plasma concentrations also appear to influence selective nucleotide blockade. Zaharko et al. [20] , evaluating the biochemical aspects of low-vs high-dose continuous MTX infusion in mice, noted that at the lower dose a thymine block was produced at sustained plasma MTX concentrations of 10 nmoVL; at the higher dose, which produced a sustained plasma MTX concentration of 100 nmollL, production of both purine and thymidylate was blocked. Duration of exposure appears to be as critical as drug concentration exposure. Pinedo and Chabner [21] showed that the nadir for depletion of nucleated bone marrow cells depended on the drug concentration as well as the length of exposure in mice treated with constant-infusion MTX. A nadir decrease to 30% of control cells in bone marrow was reached with infusions that resulting in MTX plasma concentrations of 10 000 nmollL for 12 h, 1000 nmolIL for 24 h, 100 nmolfL for 48 h, and 10 nmol/L for 72 h. Surprisingly in this study, comparison of the Aggressive hydration is necessary along with urine alkalinization (discussed later) to promote brisk diuresis and to prevent intratubular precipitation of MTX (Fig. 3) , MTX-related renal failure, and subsequent toxicity secondary to delayed MTX clearance.
In HDMTX therapy, hydration takes on a more significant role because of the production of 7-OH-MTX, a metabolite of MTX not appreciably produced at conventional doses of MTX [42, 43] . The limited aqueous solubility of 7-OH-MTX may contribute to HDMTX-related renal toxicity 
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Treon and Chabner: High-dose methotrexate therapy [42, 43] . The effect of hydration on HDMTX pharmacokinetics was the subject of a study by Ferrari et al. [44] , who examined the relation of higher (2 L/m2) vs lower dose (1.5 L/m2) hydration on MTX plasma concentrations and MTX elimination. Their studies showed that excess hydration decreased plasma MTX (427 vs 585 tmoVL) when sampled at the end of the HDMTX infusion, whereas plasma concentrations 14 and 38 h later were not statistically different. Although excess hydration was noted to decrease peak MTX concentrations substantially, no additional toxicities were noted in the group receiving the lower amount of hydration. The optimal urine flow to ensure adequate renal excretion of MTX, as analyzed by Sasaki et a!. [45] in children receiving HDMTX, should be 0.1-1.8 mL/m2 per minute with a urine pH of 7.0 to ensure adequate MTX clearance.
Interestingly, a considerably higher flow was needed with lower urine pH, because of the marked decrease in drug solubility at more acidic pH.
MAINTAINING ALKALINE URINE
MTX and its metabolite 7-OH-MTX, which is seen predominantly with HDMTX therapy, show respectively 20-and 12-fold increased solubility when pH increases from 5.0 to 7.0 [42] . Renal tubular precipitation of MTX and 7-OH-MTX (Fig. 3 ) occurs in an acidic urine environment (pH <5.7) [38] ; this likely contributes to renal failure and delayed MTX clearance [14, 42, 43] .Pitman and Frei [14] showed that urinary alkalinization achieved with oral sodium bicarbonate resulted in substantially less nephrotoxicity and myelotoxicity when historically compared with patients without urinary alkalization.
A pH of >7.0 was maintained in this study, in addition to rigorous hydration (>3 L/day). Interestingly, Sand et al. [46] showed that maintaining high urinary flow was not as important as maintaining an alkaline urine pH in promoting MTX clearance.
AVOIDING DRUG INTERACTIONS
About 50% of MTX is bound to serum proteins, a fairly constant proportion irrespective of serum MTX concentration [46] . Toxicity may occur in HDMTX treatment if drugs having the potential to displace MTX from serum proteins are administered with HDMTX-e.g., salicylates, phenylbutazone, phenytoin, and sulfonamides [47] . Administration of HDMTX with nonsteroidal anti-inflammatory drugs is especially to be avoided because of the potential to inhibit MTX renal clearance and to displace serum-bound MTX, thereby creating higher and prolonged MTX concentrations [48] . Thyss et al. [49] reported 3 deaths in a series of 36 patients who inadvertently received the nonsteroidal anti-inflammatory ketoprofen during HDMTX administration.
Use of concomitant probenecid should also be avoided with HDMTX because it inhibits renal tubular transport of MTX [50] , as would potentially nephrotoxic drugs such as gentamicin and cisplatin [47] .
DRAINAGE OF THIRD-SPACE FLUIDS
The presence of third-space fluids (e.g., ascites and pleural effusions) constitutes an important contraindication to the administration of HDMTX. Wan Fig. 4 ). Various cutoff points based on the half-life of MTX plasma or serum disappearance have been used for initiating action to prevent or minimize toxicity.
Stoller et al. [39] measured MTX plasma clearance in 78 patients (395 treatment courses) who received HDMTX in a 6-h infusion. By 48 h after starting the infusion, an MTX plasma concentration of 0.9 moVL was associated with a higher frequency of toxicity: About one-half of the patients who had a higher MTX concentration experienced severe myelotoxicity [39] .Other cutoff points have also been identified as signifying MTX concentrations that place patients at higher risk of toxicity; again, these vary with the HDMTX regimen used and are based on time points from 18 to 72 h post-HDMTX infusion start [52] [53] [54] [55] .
Management of HDMTX-RelatedToxicity

LEUCOVORIN "RESCUE"
Use of HDMTX would be lethal were it not followed by the administration of reduced folates (such as LV) to circumvent the metabolic blockade imposed by MTX [18] . The use of LV rescue was first introduced by Goldin et al. [56] , who showed that drug-related deaths in mice inoculated with Ll2 10 leukemic cells were substantially less when LV was administered with MTX. However, compared with the animals that had received MTX alone, overall survival was improved only in animals that Courtesyof David Harmon,Massachusetts GeneralHospital. [6, 10, 57] .
LV in vivo is converted to MTHF, which ordinarily serves as the major circulating reduced folate, and which acts to replete the reduced intracellular folate pool required for the production of thymidylate and the purines [18] . Rescue with MTHF has also been shown [58] ; however, LV, a more stable form of reduced folate, is the preferred pharmacological agent for abrogating MTX-related toxicity. LV is a mixture of stereoisomers, of which only the L-isomer is metabolically active; thus only -50% of a given dose is actually active drug [59] .
The dose and frequency of LV rescue have been developed empirically and differ according to the regimen of HDMTX used (Table  1) . Bertino [60] showed that DNA synthesis is effectively restored in healthy human marrow cells exposed to 2 jmol/L MTX when LV is added at a 10-fold excess.
In addition to repleting reduced intracellular folate pools, excess extracellular concentrations of LV may promote "rescue" by competing with MTX for active transport into cells [61] . Duration of the LV rescue is also important and should be continued until serum MTX concentrations are <10 nmoL/L; higher concentrations inhibit bone marrow proliferation [19] . LV rescue is logically continued until plasma MTX falls below 10 nmollL, at which point circulating natural folates are believed to be sufficient to prevent cytotoxicity [62] . 
